Company intelligence / Profile preview
Skyline Biosciences
Chicago, Illinois, United Statesskylinebiosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Skyline Biosciences is developing first-in-kind therapies for premalignant and malignant oral lesions, aiming to extend and improve quality of life for patients with oral oncology conditions. Its lead program, SBS-101, was in a Phase I clinical trial to evaluate safety and pharmacokinetics in patients with oral pre-malignant lesions; however, the trial was withdrawn before completion and no clinical data has been reported[1][2].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (oral adhesive film)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Paragon Biosciences
Beyond the preview
Go deeper on Skyline Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skyline Biosciences.